oa Professional Nursing Today - TB Alliance enters into collaboration with sanofi-aventis to fight tuberculosis
AstraZeneca and Nomura Phase4 Ventures announce creation of new company "Albireo" : industry news



The Global Alliance for TB Drug Development (TB Alliance) and sanofi-aventis announced today that they have entered into a collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis (TB). The TB Alliance is a not-for-profit, product development partnership, whose goal is the development of new TB drugs.

AstraZeneca and Nomura Phase4 Ventures have announced the signing of a deal to form Albireo, a biotechnology company focused on developing new treatments for gastrointestinal (GI) disorders. The spinout is a result of AstraZeneca's previously announced strategic decision to concentrate on Nexiam and internal GI research focussed on Gastroesophageal Reflux Disease (GORD).


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error